BostonGene Showcases AI-Driven Drug Development at AACR Annual Meeting
BostonGene, a leader in AI-driven cancer research, is set to present 13 abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2026. The company will demonstrate its AI foundation model for tumor and immune biology, which integrates genomic, transcriptomic, and spatial insights to accelerate drug discovery and optimize patient stratification. Key presentations include the use of AI-based tools for precision patient stratification, target identification, and prediction of drug-induced tissue dynamics. BostonGene's research highlights the potential of AI to transform the pharmaceutical pipeline by providing biologically grounded insights from early discovery through late-stage clinical trials. 
